Prostanoid signal transduction and gene expression in the endothelium: Role in cardiovascular diseases

Cardiovascular Research

Volumn 70, Issue 3, 2006, Pages 446-456

  Alfranca, Arántzazu ^a,b   Iñiguez, Miguel A ^a   Fresno, Manuel ^a   Redondo, Juan Miguel ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Angiogenesis; Atherosclerosis; Gene expression; Prostaglandins; Signal transduction

Indexed keywords

PROSTACYCLIN RECEPTOR; PROSTAGLANDIN D2; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN J2; PROSTANOID; PROSTANOID RECEPTOR; THROMBOXANE A2 RECEPTOR;

ANGIOGENESIS; ATHEROSCLEROSIS; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CELL SURFACE; CELL TYPE; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME ACTIVITY; GENE EXPRESSION; HOMEOSTASIS; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDINS; SIGNAL TRANSDUCTION;

EID: 33747466079     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2005.12.020     Document Type: Review

References (98)

1. Galley H.F., and Webster N.R. Physiology of the endothelium. Br J Anaesth 93 (2004) 105-113
2. Vadas M.A., and Gamble J.R. Endothelial adhesion molecules in atherogenesis. Circ Res 79 (1996) 1216-1217
3. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6 (2000) 389-395
4. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
5. Smyth E.M., Austin S.C., Reilly M.P., and FitzGerald G.A. Internalization and sequestration of the human prostacyclin receptor. J Biol Chem 275 (2000) 2037-2045
6. Parent J.L., Labrecque P., Orsini M., and Benovic J.L. Internalization of the TXA2 receptor alpha and beta isoforms. Role of the differentially spliced COOH terminus in agonist-promoted receptor internalization. J Biol Chem 274 (1999) 941-948
7. Walsh M.T., Foley J.F., and Kinsella J.P. The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for prostacyclin-mediated desensitization. J Biol Chem 275 (2000) 20412-20423
8. Ashton A.W., Cheng Y., Helisch A., and Ware J.A. Thromboxane A2 receptor agonists antagonize the proangiogenic effects of fibroblast growth factor-2: role of receptor internalization, thrombospondin-1, and alpha(v)beta3. Circ Res 94 (2004) 735-742
9. Gao Y., Yokota R., Tang S., Ashton A.W., and Ware J.A. Reversal of angiogenesis in vitro, induction of apoptosis, and inhibition of AKT phosphorylation in endothelial cells by thromboxane A(2). Circ Res 87 (2000) 739-745
10. Offermanns S., Laugwitz K.L., Spicher K., and Schultz G. G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci U S A 91 (1994) 504-508
11. Bos C.L., Richel D.J., Ritsema T., Peppelenbosch M.P., and Versteeg H.H. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 36 (2004) 1187-1205
12. Ashton A.W., and Ware J.A. Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ Res 95 (2004) 372-379
13. Dormond O., Bezzi M., Mariotti A., and Ruegg C. Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J Biol Chem 277 (2002) 45838-45846
14. Battacharya M., Peri K., Ribeiro-Da-Silva A., Almazan G., Shichi H., Hou X., et al. Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. J Biol Chem 274 (1999) 15719-15724
15. Watabe A., Sugimoto Y., Honda A., Irie A., Namba T., Negishi M., et al. Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E2 receptor. J Biol Chem 268 (1993) 20175-20178
16. Takayama K., Garcia-Cardena G., Sukhova G.K., Comander J., Gimbrone Jr. M.A., and Libby P. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 277 (2002) 44147-44154
17. Pillinger M.H., Rosenthal P.B., Tolani S.N., Apsel B., Dinsell V., Greenberg J., et al. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J Immunol 171 (2003) 6080-6089
18. Fujino H., West K.A., and Regan J.W. Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J Biol Chem 277 (2002) 2614-2619
19. Fujino H., Xu W., and Regan J.W. Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 278 (2003) 12151-12156
20. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 79 (1999) 1193-1226
21. Burkey T.H., and Regan J.W. Activation of mitogen-activated protein kinase by the human prostaglandin EP3A receptor. Biochem Biophys Res Commun 211 (1995) 152-158
22. Yamaki T., Endoh K., Miyahara M., Nagamine I., Huong N., Sakurai H., et al. Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3. Cancer Lett 214 (2004) 115-120
23. Hatae N., Sugimoto Y., and Ichikawa A. Prostaglandin receptors: advances in the study of EP3 receptor signaling. J Biochem (Tokyo) 131 (2002) 781-784
24. Faour W.H., He Y., He Q.W., De Ladurantaye M., Quintero M., Mancini A., et al. Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J Biol Chem 276 (2001) 31720-31731
25. Pai R., Szabo I.L., Soreghan B.A., Atay S., Kawanaka H., and Tarnawski A.S. PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun 286 (2001) 923-928
26. Dumais N., Bounou S., Olivier M., and Tremblay M. Prostaglandin E(2)-mediated activation of HIV-1 long terminal repeat transcription in human T cells necessitates CCAAT/enhancer binding protein (C/EBP) binding sites in addition to cooperative interactions between C/EBPbeta and cyclic adenosine 5′-monophosphate response element binding protein. J Immunol 168 (2002) 274-282
27. Liu X.H., Kirschenbaum A., Lu M., Yao S., Dosoretz A., Holland J.F., et al. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 277 (2002) 50081-50086
28. Buchanan F.G., Wang D., Bargiacchi F., and DuBois R.N. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278 (2003) 35451-35457
29. Pai R., Soreghan B.A., Szabo I.L., Pavelka M., Baatar D., and Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8 (2002) 289-293
30. Wang D., Wang H., Shi Q., Katkuri S., Walhi W., Desvergne B., et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6 (2004) 285-295
31. Desai S., April H., Nwaneshiudu C., and Ashby B. Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration. Mol Pharmacol 58 (2000) 1279-1286
32. Komhoff M., Lesener B., Nakao K., Seyberth H.W., and Nusing R.M. Localization of the prostacyclin receptor in human kidney. Kidney Int 54 (1998) 1899-1908
33. Jones D.A., Benjamin C.W., and Linseman D.A. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 48 (1995) 890-896
34. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94 (1997) 4312-4317
35. 2+ mobilization in osteoblasts: regulation by protein kinase C. Prostaglandins Leukot Essent Fat Acids 61 (1999) 189-194
36. Chen Y.E., Fu M., Zhang J., Zhu X., Lin Y., Akinbami M.A., et al. Peroxisome proliferator-activated receptors and the cardiovascular system. Vitam Horm 66 (2003) 157-188
37. Pineda I., Chinetti G., Duval C., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol 12 (2001) 245-254
38. Ricote M., Li A.C., Wilson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
39. Grau R., Iniguez M.A., and Fresno M. Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism. Cancer Res 64 (2004) 5162-5171
40. Oliva J.L., Perez-Sala D., Castrillo A., Martínez N., Cañada F.J., Bosca L., et al. The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and activates H-Ras. Proc Natl Acad Sci USA 100 (2003) 4772-4777
41. Castrillo A., Través P., Martín-Sanz P., Parkinson S.J., Parker P.J., and Bosca L. Potentiation of protein kinase C zeta activity by 15-deoxy-delta(12,14)-prostaglandin J(2) induces an imbalance between mitogen-activated protein kinases and NF-kappa B that promotes apoptosis in macrophages. Mol Cell Biol 23 (2003) 1196-1208
42. Caivano M., Rodriguez C., Cohen P., and Alemany S. 15-Deoxy-Delta12,14-prostaglandin J2 regulates endogenous Cot MAPK kinase 1 activity induced by lipopolysaccharide. J Biol Chem 278 (2003) 52124-52130
43. Chen D.B., Westfall S.D., Fong H., Roberson M.S., and Davis J.S. Prostaglandin F2alpha stimulates the Raf/MEK1/mitogen-activated protein kinase signaling cascade in bovine luteal cells. Endocrinology 139 (1998) 3876-3885
44. Horsley V., and Pavlath G.K. Prostaglandin F alpha stimulates growth of skeletal muscle cells via an NFATC2-dependent pathway. J Cell Biol 161 (2003) 111-118
45. Ohmichi M., Koike K., Kimura A., Masuhara K., Ikegami H., Ikebuchi Y., et al. Role of mitogen-activated protein kinase pathway in prostaglandin F2alpha-induced rat puerperal uterine contraction. Endocrinology 138 (1997) 3103-3111
46. Pierce K.L., Fujino H., Srinivasan D., and Regan J.W. Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton. J Biol Chem 274 (1999) 35944-35949
47. Fujino H., and Regan J.W. FP prostanoid receptor activation of a T-cell factor/beta-catenin signaling pathway. J Biol Chem 276 (2001) 12489-12492
48. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation (2002) 1135-1143
49. Stemme V., Swedenborg J., Claesson H., and Hansson G.K. Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg 20 (2000) 146-152
50. Garlichs C.D., Geis T., Goppelt-Struebe M., Eskafi S., Schmidt A., Schulze-Koops H., et al. Induction of cyclooxygenase-2 and enhanced release of prostaglandin E(2) and I(2) in human endothelial cells by engagement of CD40. Atherosclerosis 163 (2002) 9-16
51. Eligini S., Colli S., Basso F., Sironi L., and Tremoli E. Oxidized low density lipoprotein suppresses expression of inducible cyclooxygenase in human macrophages. Arterioscler Thromb Vasc Biol 19 (1999) 1719-1725
52. Linton M.F., and Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol 4 (2004) 116-123
53. Burleigh M.E., Babaev V.R., Oates J.A., Harris R.C., Gautam S., Riendeau D., et al. Cyclooxygenase-2 promotes early atherosclerotic formation in LDL receptor-deficient mice. Circulation 105 (2002) 1816-1823
54. Dong Z., Chapman S., Brown A., Frenette P., Hynes R., and Wagner D. The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 102 1 (1998) 145-152
55. Cybulsky M., Iiyama K., Li H., Zhu S., Chen M., Iiyama M., et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107 (2001) 1255-1262
56. Collins R.G., Velji R., Guevara N.V., Hicks M.J., Chan L., and Beaudet A.L. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 191 (2000) 189-194
57. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein-deficient mice. Mol Cell 2 (1998) 275-281
58. Nawa T., Nawa M.T., Cai Y., Zhang C., Uchimura I., Narumi S., et al. Repression of TNF-alpha-induced E-selectin expression by PPAR activators: involvement of transcriptional repressor LRF-1/ATF3. Biochem Biophys Res Commun 275 (2000) 406-411
59. Chen N.G., and Han X. Dual function of troglitazone in ICAM-1 gene expression in human vascular endothelium. Biochem Biophys Res Commun 282 (2001) 717-722
60. Verrier E., Wang L., Wadham C., Albanese N., Hahn C., Gamble J.R., et al. PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase. Circ Res 94 (2004) 1515-1522
61. Migita H., and Morser J. 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) signals through retinoic acid receptor-related orphan receptor-alpha but not peroxisome proliferator-activated receptor-gamma in human vascular endothelial cells: the effect of 15d-PGJ2 on tumor necrosis factor-alpha-induced gene expression. Arterioscler Thromb Vasc Biol 25 (2005) 710-716
62. Goya K., Otsuki M., Xu X., and Kasayama S. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism 52 (2003) 192-198
63. Rival Y., Beneteau N., Taillandier T., Pezet M., Dupont-Passelaigue E., Patoiseau J.F., et al. PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435 (2002) 143-151
64. Zhang J., Fu M., Zhao L., and Chen Y.E. 15-Deoxy-prostaglandin J(2) inhibits PDGF-A and -B chain expression in human vascular endothelial cells independent of PPAR gamma. Biochem Biophys Res Commun 298 (2002) 128-132
65. Marx N., Mach F., Sauty A., Leung J.H., Sarafi M.N., Ransohoff R.M., et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 164 (2000) 6503-6508
66. Kwak B.R., Myit S., Mulhaupt F., Veillard N., Rufer N., Roosnek E., et al. PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells. Circ Res 90 (2002) 356-362
67. Eligini S., Banfi C., Brambilla M., Camera M., Barbieri S.S., Poma F., et al. 15-deoxy-delta12,14-Prostaglandin J2 inhibits tissue factor expression in human macrophages and endothelial cells: evidence for ERK1/2 signaling pathway blockade. Thromb Haemost 88 (2002) 524-532
68. Xie S., O'Regan D.J., Kakkar V.V., and Scully M.F. 15 deoxy delta12,14 PGJ2 induces procoagulant activity in cultured human endothelial cells. Thromb Haemost 87 (2002) 523-529
69. Marx N., Bourcier T., Sukhova G.K., Libby P., and Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19 (1999) 546-551
70. Glass C.K., and Witztum J.L. Atherosclerosis: the road ahead. Cell (2001) 503-516
71. Cipollone F., Prontera C., Pini B., Marini M., Fazia M., De Cesare D., et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-dependent plaque instability. Circulation 104 (2001) 921-927
72. Cipollone F., Fazia M., Iezzi A., Pini B., Cuccurullo C., Zucchelli G.C., et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloprotease activity. Circulation 109 (2004) 1482-1488
73. Moulton K.S., Heller E., Konerding M.A., Flynn E., Palinski W., and Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99 (1999) 1726-1732
74. Bishop-Bailey D., and Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 274 (1999) 17042-17048
75. Taba Y., Miyagi M., Miwa Y., Inoue H., Takahashi-Yanaga F., Morimoto S., et al. 15-deoxy-delta 12,14-prostaglandin J2 and laminar fluid shear stress stabilize c-IAP1 in vascular endothelial cells. Am J Physiol Heart Circ Physiol 285 (2003) H38-H46
76. Wise H., Wong Y.H., and Jones R.L. Prostanoid signal integration and cross talk. Neurosignals 11 (2002) 20-28
77. Huang P.L., Huang Z., and Mashimo H. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377 (1995) 239-242
78. Murata T., Ushikubi T., Matsuoka M., Hirata A., Yamasaki Y., Sugimoto A., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 (1997) 678-682
79. Panza J.A., Casino P.R., Kilcoyne C.M., and Quyyumi A.A. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 87 (1993) 1468-1474
80. Polikandriotis J.A., Mazzella L.J., Rupnow H.L., and Hart C.M. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 25 (2005) 1810-1816
81. Jozkowicz A., Nigisch A., Winter B., Weigel G., Huk I., and Dulak J. 15-deoxy-delta12, 14-prostaglandin-J2 inhibits expression of eNOS in human endothelial cells. Prostaglandins Other Lipid Mediat 74 (2004) 11-28
82. Spieker L.E., Noll G., Ruschitzka F.T., Maier W., and Luscher T.F. Working under pressure: the vascular endothelium in arterial hypertension. J Hum Hypertens 14 (2000) 617-630
83. Delerive P., Martin-Nizard F., Chinetti G., Trottein F., Fruchart J.C., Najib J., et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85 (1999) 394-402
84. Razandi M., Pedram A., Rubin T., and Levin E.R. PGE2 and PGI2 inhibit ET-1 secretion from endothelial cells by stimulating particulate guanylate cyclase. Am J Physiol 270 (1996) H1342-H1349
85. Kennedy C., Zhang Y., Brandon S., Guan Y., Coffee K., Funk C.D., et al. Salt-sensitive hypertension and reduced fertility in mice lacking the rostaglandin EP2 receptor. Nat Med 5 (1999) 217-220
86. Iniguez M.A., Rodriguez A., Volpert O.V., Fresno M., and Redondo J.M. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 9 (2003) 73-78
87. Sonoshita M., Takaku K., Sasaki N., Sugimoto Y., Ushikubi F., Narumiya S., et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7 (2001) 1048-1051
88. Majima M., Amano H., and Hayashi I. Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends Pharmacol Sci 24 (2003) 524-529
89. Salcedo R., Zhang X., Young H.A., Michael N., Wasserman K., Ma W.H., et al. Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood 102 (2003) 1966-1977
90. Inoue M., Itoh H., Tanaka T., Chun T.H., Doi K., Fukunaga Y., et al. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-gamma. Arterioscler Thromb Vasc Biol 21 (2001) 560-566
91. Xin X., Yang S., Kowalski J., and Gerritsen M.E. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274 (1999) 9116-9121
92. Murata T., He S., Hangai M., Ishibashi T., Xi X.P., Kim S., et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 41 (2000) 2309-2317
93. Quesada A.J., Nelius T., Yap R., Zaichuk T.A., Alfranca A., Filleur S., et al. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ 12 (2005) 649-658
94. Huang H., Campbell S.C., Bedford D.F., Nelius T., Veliceasa D., Shroff E.H., et al. Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol Cancer Res 2 (2004) 541-550
95. Daniel T.O., Liu H., Morrow J.D., Crews B.C., and Marnett L.J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59 (1999) 4574-4577
96. Thomas D.W., Mannon R.B., Mannon P.J., Latour A., Oliver J.A., Hoffman M., et al. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest 102 (1998) 1994-2001
97. Nguyen M., Camenisch T., Snouwaert J.N., Hicks E., Coffman T.M., Anderson P.W., et al. The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. Nature 390 (1997) 78-81
98. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4 (1999) 585-595